Twitter

Archive for the ‘Cancer Clinical Trials’ Category


Crizotinib Improves Progression-Free Survival in Some Patients with Advanced Lung Cancer

Results from an international phase III trial show that crizotinib (Xalkori®) substantially extends progression-free survival in previously treated patients with advanced lung cancer whose tumors have a specific genetic mutation.

Read More...

Women with Breast Cancer Micrometastases in Their Sentinel Lymph Nodes May Not Need Axillary Dissection

Results from a randomized clinical trial showed that women with breast cancer and only micrometastases in their sentinel lymph nodes who received axillary lymph node dissection had more side effects but no improvement in disease-free survival compared with women who had no further lymph node surgery.

Read More...

Potentially Less Toxic Adjuvant Chemotherapy for Women with Breast Cancer

In this phase III trial, women with resected HER2-negative breast cancer that has either spread to nearby lymph nodes or has characteristics associated with a high risk of recurrence will be randomly assigned to receive one of four anthracycline-based chemotherapy regimens or six courses of docetaxel and cyclophosphamide.

Read More...

Electrocautery Superior to Topical Treatments for Precancerous Anal Lesions

Results from a randomized clinical trial conducted in Amsterdam suggest that electrocautery is better than topical imiquimod or fluorouracil at treating potentially precancerous anal lesions in HIV-positive men who have sex with men.

Read More...

New Combination Therapy for Untreated Multiple Myeloma

In this phase II trial, people with newly diagnosed multiple myeloma will be treated with carfilzomib, lenalidomide, and dexamethasone for eight 28-day treatment cycles.

Read More...

Refining Post-Surgical Therapy for Women with Lymph Node-Positive Breast Cancer

In this phase III trial, women with HER2-negative, HR-positive breast cancer and 1-3 positive lymph nodes with recurrence scores of 25 or lower will be randomly assigned either to undergo adjuvant chemotherapy before starting endocrine therapy or to begin endocrine therapy without chemotherapy.

Read More...

Refining Post-Surgical Therapy for Women with Lymph Node-Positive Breast Cancer

In this phase III trial, women with HER2-negative, HR-positive breast cancer and 1-3 positive lymph nodes with recurrence scores of 25 or lower will be randomly assigned either to undergo adjuvant chemotherapy before starting endocrine therapy or to begin endocrine therapy without chemotherapy.

Read More...

New Drug Shows Promise against Drug-Resistant Leukemias

A new drug called ponatinib may be a new treatment option for patients with chronic myeloid leukemia (CML) that is resistant to other therapies, according to results of two early clinical trials.

Read More...

Treating Patients with High-Risk Smoldering Myeloma

In this phase III clinical trial, patients with smoldering myeloma classified as high risk for progression will be randomly assigned to undergo standard observation or six 4-week courses of treatment with the drug lenalidomide.

Read More...

Treating Patients with High-Risk Smoldering Myeloma

In this phase III clinical trial, patients with smoldering myeloma classified as high risk for progression will be randomly assigned to undergo standard observation or six 4-week courses of treatment with the drug lenalidomide.

Read More...